NEWLINK GENETICS CORP Development Agreements

27 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
FIRST AMENDED AND RESTATED CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2016
Amendment to Development and Manufacturing Terms and Conditions
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2014
Development and Process Transfer Program Leading to Commercial Manufacturing for algenpantucel-L HyperAcute" Pancreas Technical Transfer, Verification / Process Development,...
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2014
CELL THERAPY DEVELOPMENT, MANUFACTURING AND/OR TISSUE PROCESSING TERMS AND CONDITIONS BETWEEN WuXi AppTec, Inc. and NewLink Genetics Corporation
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
NY
2014
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
DC
2012
AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #8 To Letter of Intent for Proposed CRADA #02166 Preclinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of 1-Methyl [d]-Tryptophan as an Anticancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #2 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of 1-Methyl-[d]-Tryptophan as an Anti-Cancer Agent
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER RESEARCH TRIANGLE PARK DIVISION P.O. BOX 12211 RESEARCH TRIANGLE PARK, NORTH...
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
DEPARTMENT OF THE ARMY U.S. ARMY RESEARCH, DEVELOPMENT AND ENGINEERING COMMAND ACQUISITION CENTER
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
AMENDMENT #7 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2011
$6,000,000 IOWA VALUES FUND (IVF) CONTRACT BY AND BETWEEN NEWLINK GENETICS CORPORATION AND THE IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT DATED AS OF MARCH 18, 2005
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
IA
2010
AMENDMENT #6 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #5 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #4 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #3 To Letter of Intent for Proposed CRADA #2166 Preclinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
AMENDMENT #1 To Letter of Intent for Proposed CRADA #2166 Pre-Clinical and Clinical Development of [*]
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
2010
Cooperative Research and Development Agreement (CRADA #1901) [*] NCI Principal Investigator John C. Morris, M.D. Metabolism Branch, CCR, NCI Collaborator PrincipalInvestigator...
Development Agreements
NEWLINK GENETICS CORP
Biotechnology
DC
2010